The stock may react positively to the strong 2026 revenue growth guidance, but traders should be cautious of the projected decline in Adjusted EBITDA and near-term margin pressure. Monitor the execution of the operating cost reduction plan and the integration of new $900 million in revenue.
How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Feb 25 $3.14entry
- T+1 · 9mo ago +5.73%α +6.28% · $3.32
- T+5 · 9mo ago +13.06%α +14.16% · $3.55
- T+20 · 8mo ago −27.71%α −22.47% · $2.27
- T+60 · 6mo ago +22.93%α +15.98% · $3.86
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Evolent Health reported a significant year-over-year decline in revenue and net loss for 2025, driven by goodwill and other impairments. However, the company guided for approximately 30% revenue growth in 2026, citing strong customer retention and a robust pipeline. Adjusted EBITDA remained stable at $151 million, but 2026 guidance projects a decline to $110-$140 million due to near-term investments and membership changes.
Key Financial Metrics
Key Facts
- 2025 revenue declined 26.5% YoY to $1.876 billion, primarily due to a $398 million goodwill impairment.
- Adjusted EBITDA was $151.2 million in 2025, flat year-over-year, with a stable 8.1% margin.
- The company guided for 2026 revenue of $2.4-$2.6 billion (approx. 30% growth) and Adjusted EBITDA of $110-$140 million.
- Management cited $900 million in new Performance Suite revenue for 2026 but expects near-term margin pressure.
- Net loss attributable to common shareholders was $579.4 million in 2025, compared to a loss of $93.5 million in 2024.
Financial Impact
Revenue down 26.5% YoY to $1.876B; Adjusted EBITDA flat at $151.2M; 2026 revenue guidance of $2.4B-$2.6B implies ~30% growth.
Segment Breakdown
| Segment | Revenue |
|---|---|
| Performance Suite | $1.1B |
| Specialty Technology and Services Suite | $353.2M |
| Administrative Services | $226.7M |
| Cases | $169.0M |
Risk Factors
- The significant decline in GAAP revenue and net loss raises concerns about underlying business health.
- The 2026 Adjusted EBITDA guidance is below 2025 levels, indicating near-term profitability challenges.
- The company's forecast is dependent on successfully managing the impact of new contract reserving and customer membership decreases.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001628908-26-000014 |
| Document: evh-20260224.htm | 0001628908-26-000014 |
| Document: 0001628908-26-000014-index-headers.html | 0001628908-26-000014 |
| Document: 0001628908-26-000014-index.html | 0001628908-26-000014 |
| Document: 0001628908-26-000014.txt | 0001628908-26-000014 |
Track record
8 reports on EVH
Filters
- Nov 16, 2026today SC 13G/A Bearish 4/10 Entry $4.82 Now $4.83 −0.31% settles Dec 15
- Nov 13, 20263d ago SC 13G/A Bearish 5/10 Entry $4.74 Now $4.83 −1.90% settles Dec 15
- Nov 5, 202611d ago 8-K Neutral 5/10 No price data
- Nov 5, 202611d ago Press Release Neutral 5/10 Entry $4.54 Now $4.83 +6.39% settles Dec 4
- Aug 6, 202614w ago 8-K Mixed 6/10 Entry $3.59 to $4.26 Now $4.83 +34.54% ▲ +18.66% +18.06% vs SPY
- Jul 8, 202618w ago Press Release Neutral 1/10 Entry $5.63 to $3.59 Now $4.83 −14.21% ▼ −36.23% −38.48% vs SPY
- Apr 24, 202629w ago DEFA14A Neutral 2/10 Entry $3.47 to $3.83 Now $4.83 +39.19% ▲ +10.37% +5.42% vs SPY
- Feb 24, 202637w ago 8-K Mixed 6/10 Viewing Entry $3.14 to $2.27 Now $4.83 +53.82% ▼ −27.71% −22.47% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers